Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma
R Ettari, M Zappalà, S Grasso, C Musolino… - Pharmacology & …, 2018 - Elsevier
The ubiquitin-proteasome system (UPS) is the major non-lysosomal proteolytic system for
the degradation of abnormal or damaged proteins no longer required. The proteasome is …
the degradation of abnormal or damaged proteins no longer required. The proteasome is …
Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases
The immunoproteasome is predominantly expressed in monocytes and lymphocytes and is
responsible for the generation of antigenic peptides for cell-mediated immunity. Upon the …
responsible for the generation of antigenic peptides for cell-mediated immunity. Upon the …
Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases
J Xi, R Zhuang, L Kong, R He, H Zhu… - European Journal of …, 2019 - Elsevier
The immunoproteasome, a specialized form of proteasome, is mainly expressed in
lymphocytes and monocytes of jawed vertebrates and responsible for the generation of …
lymphocytes and monocytes of jawed vertebrates and responsible for the generation of …
The immunoproteasome: an emerging therapeutic target
The proteasome, a large multisubunit protease complex, has been extensively investigated
over the years, greatly enhancing our understanding of critical roles that the proteasome …
over the years, greatly enhancing our understanding of critical roles that the proteasome …
The immunoproteasome as a target in hematologic malignancies
DJ Kuhn, RZ Orlowski - Seminars in hematology, 2012 - Elsevier
Suppression of proteasome function with the first-in-class small molecule inhibitor
bortezomib is a rational therapeutic strategy against several hematologic malignancies …
bortezomib is a rational therapeutic strategy against several hematologic malignancies …
Inhibitors of the immunoproteasome: current status and future directions
The ubiquitin-proteasome system (UPS) plays a vital role in maintaining protein
homeostasis and regulating numerous cellular processes. The proteasome, a multi-protease …
homeostasis and regulating numerous cellular processes. The proteasome, a multi-protease …
Immunoproteasome function in normal and malignant hematopoiesis
The ubiquitin–proteasome system (UPS) is a central part of protein homeostasis, degrading
not only misfolded or oxidized proteins but also proteins with essential functions. The fact …
not only misfolded or oxidized proteins but also proteins with essential functions. The fact …
New insights into the function of the immunoproteasome in immune and nonimmune cells
H Kimura, P Caturegli, M Takahashi… - Journal of immunology …, 2015 - Wiley Online Library
The immunoproteasome is a highly efficient proteolytic machinery derived from the
constitutive proteasome and is abundantly expressed in immune cells. The …
constitutive proteasome and is abundantly expressed in immune cells. The …
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and …
DJ Kuhn, SA Hunsucker, Q Chen… - Blood, The Journal …, 2009 - ashpublications.org
Proteasome inhibition is a validated strategy for therapy of multiple myeloma, but this
disease remains challenging as relapses are common, and often associated with increasing …
disease remains challenging as relapses are common, and often associated with increasing …
Development of proteasome inhibitors in oncology and autoimmune diseases.
MK Bennett, CJ Kirk - Current opinion in drug discovery & …, 2008 - europepmc.org
The proteasome is a multicatalytic protease complex that mediates the controlled
degradation of intracellular proteins, including key components of pathways that contribute …
degradation of intracellular proteins, including key components of pathways that contribute …
相关搜索
- selective inhibitors promising strategy
- potent strategy proteasome inhibitors
- autoimmune diseases proteasome inhibitors
- immunoproteasome inhibitors cell viability
- immunoproteasome inhibitors design and evaluation
- immunoproteasome inhibitors compensatory process
- selective inhibitors hematologic malignancies
- targeted inhibition proteasome inhibitors